



## SDI FINAL EVALUATION FORM 1.1

### PART 1:

Journal Name:	<a href="#">British Journal of Medicine and Medical Research</a>
Manuscript Number:	2014_BJMMR_13820
Title of the Manuscript:	Dose-dependent Modulation of Lipid Parameters and Inflammatory Biomarkers by $\delta$ -Tocotrienol in Hypercholesterolemic Subjects

### PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<p>Since all subjects were studied simultaneously and the study design is a fixed sequence it's entirely possible that the significant reduction in LDL seen with the 250 mg dose. Please mention this possibility in the Discussion.</p> <p>It's not clear why such extensive revision to the text was made unless there is another review that I am not aware of. The first two paragraphs of the Introduction are unnecessary and there are multiple inaccuracies. I would recommend replacing with the introduction from the original submission.</p> <p>Table 4. Include gene expression data for AHA step 1 diet if available.</p> <p>Tables 3 and 5 Do the P values represent comparison with Baseline or AHA Step 1 period? Please indicate in the notes to each table.</p>	<p>This comment is not clear. The significant reduction in serum LDL-cholesterol (18%, <math>P &lt; 0.001</math>) level with 250 mg/d dose has been reported in Abstract (Page # 2), and Results (Page # 12) sections.</p> <p>We are so glad that you have pointed out about the first two paragraphs in the Introduction section. These paragraphs have been deleted according to your suggestion. Thanks.</p> <p>Values have now been added in Table 3.</p> <p><math>\delta</math>-tocotrienol treatment values were compared to baseline group (used as control).</p>